Once again, CRCM members have been incredibly productive, with no fewer than 26 articles published in the last five months, despite the summer period. All of these contributions mark significant advances in cancer research.
We thought it would be interesting to showcase them and highlight some of these projects to demonstrate the diversity and impact of the research conducted at CRCM.
Doctoral Students’ Thesis Projects
The first group of articles corresponds to the thesis projects of doctoral students in the laboratory:
• Some are still working on their theses, such as Rima Kochman from the Coulon team (Publication: “Heterozygous RPA2 variant as a novel genetic cause of telomere biology disorders”).
• Others have completed their theses in recent months, including:
– Dr. Julien Grenier from the Aurrand-Lions team (Publication: “Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML”).
– Dr. Vladimir Laletin from the Nunès/Devilliers team (Publication: “DOK1 and DOK2 regulate CD8 T cell signaling and memory formation without affecting tumor cell killing.”).
These studies respectively explore the biological and/or pathological roles of:
the replication protein A2 (RPA2) in telomere regulation,
the adhesion molecule JAM-C in leukemic stem cells,
and the docking proteins DOK1 and DOK2 in T lymphocytes.
But also translational studies
In parallel with fundamental research, translational studies are also being conducted.
For example, these efforts have led to the development of a novel therapeutic antibody targeting Nectin-4 by Marc Lopez’s group within the Predictive Oncology team, in collaboration with the Immunity and Cancer team (Publication: “ETx-22: a novel nectin-4-directed antibody drug conjugate, demonstrates safety and potent antitumor activity in low nectin-4 expressing tumors“).
This work was also featured in an article and an interview with Marc in the newspaper La Provence.
Additionally, these translational studies enabled postdoctoral researcher Nicolas Fraunhoffer, alongside the team led by Nelson Dusetti and their collaborators, to establish transcriptomic signatures for personalizing adjuvant chemotherapy in pancreatic adenocarcinomas (Publication: “Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma“).
And all the publications from recent months that advance research
COMET Department
Bard Team :
Tomasini/Vasseur Team :
“Predictive biomarkers for immune checkpoint efficacy: is multi-omics breaking the deadlock?”
Genome Integrity Department
Coulon Team :
“Heterozygous RPA2 variant as a novel genetic cause of telomere biology disorders”
Llorente Team :
“Multiple independent losses of crossover interference during yeast evolutionary history.”
Modesti Team :
OHIO Department
Aurrand-Lions Team :
Devillier / Nunes Team :
“Targeting BTN2A1 enhances Vγ9Vδ2 T-cell effector functions and triggers tumor cell pyroptosis”
“BTN2A1 targeting reprograms M2-like macrophages and TAMs via SYK and MAPK signaling”
“Molecularly matched targeted therapy: a promising approach for refractory metastatic melanoma”
Translate-it Department
Pasquier / André Team :
Benzekry / Ciccolini Team :
Iovanna / Dusetti Team :
Charafe-Jauffret Team :
“Brain metastases reirradiation.”
Bertucci / Mamessier Team :
“Endometrioid ovarian carcinoma landscape: pathological and molecular characterization”
All of this work conducted at the CRCM generates new knowledge and opens up new therapeutic perspectives for cancer patients.